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012.07.0Abstract The ﬁeld of interventional cardiology continues to progress quickly. The efﬁcacy of per-
cutaneous interventions with newer generation drug-eluting stents has advanced a lot over the last
decade. This improvement in stent performance has broadened the level of indication towards more
complex interventions such as left main and multi-vessel PCI. Major improvements continue in the
ﬁeld of medical co-therapy such as antiplatelet therapies (bivalirudin, prasugrel, and ticagrelor) and
this will further improve outcomes of PCI. The same is true for intravascular imaging such as ultra-
sound IVUS and optical coherence tomography OCT. However, interventional cardiology has
become a rather broad ﬁeld, also including alcohol septal ablation for hypertrophic obstructive car-
diomyopathy, etc. At the moment, the fastest growing area is the structural interventions, especially
for aortic valve stenosis (transcatheter aortic valve implantation TAVI) and for mitral regurgitation
(mitral clipping). This review covers recent advances in all these different ﬁelds of interventional
cardiology.
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Percutaneous coronary intervention (PCI) has guideline rec-
ommendations for the treatment of ST elevation and non-ST
elevation of myocardial infarction (MI).1 However, its role in
stable coronary disease has been the subject of reappraisal fol-
lowing the publication of the COURAGE trial, which showed
that, in patients receiving optimal medical therapy, PCI does
not improve cardiovascular outcomes, while incremental ben-
eﬁts for the quality of life disappear by 36 months.2,3 A more
recent meta-analysis of eight trials of optimal medical therapy
vs. PCI involving 7229 patients bears out the COURAGE con-
clusions by showing no signiﬁcant differences between the
groups with regard to death (9.1% vs. 8.9%), non-fatal MI
(8.1% vs. 8.9%), unplanned revascularisation (30.7% vs.
21.4%) and persistent angina (33% vs. 29%).4 Drug-eluting
stents (DESs) were used in only a minority of these patients
and may have reduced the need for further revascularisation
while improving symptomatic responses. Nevertheless, the
meta-analysis reinforces contemporary guideline advice for
optimal medical treatment as the initial treatment for stable
angina.5 Whether this will change current practice remains to
be seen, but early signs are not encouraging. Thus a US regis-
try analysis of patients undergoing PCI before (n= 173416)
and after (n= 293 795) the COURAGE report showed no
change in the proportions receiving optimal medical treatment
(43.5% vs. 44.7%).6
2. PCI versus coronary bypass surgery
The safety of PCI at hospitals without on-site cardiac surgery
has been conﬁrmed in two recent reports.7,8 Added to this is
the feasibility of PCI in increasingly complex disease and we
need look no further to explain the substantial reductions in
the rates of coronary bypass surgery (CABG) in recent years.
A recent US study of revascularisation procedures during
2001–2008 showed a 38% decline in the rates of CABG, while
PCI decreased by only 4%.9 Some have questioned whether
patients are being appropriately advised according to contem-
porary guidelines,10 a US analysis of 500 154 PCIs reporting
that, among the 28.9% of cases performed for non-acute indi-cations, only 50.4% were appropriate and that angina was not
present in many of the inappropriate cases.11 In the absence of
any evidence of prognostic beneﬁt, there can be no indication
for PCI in stable patients without angina. In patients with an-
gina, on the other hand, PCI is as effective as CABG in provid-
ing symptom relief at 12 months, judging by a recent report
from the SYNTAX investigators.12 However, CABG may
have the advantage of providing prognostic beneﬁt, recent
US registry data showing a lower 4 year mortality compared
with PCI (16.4% vs. 20.8%) in an analysis that adjusted for
selection bias.13 Of course, being a registry study, treatment
allocation was not random and any conclusions about relative
prognostic beneﬁts require caution. Nevertheless, guideline
recommendations are for surgery in complex three-vessel and
left main stem disease, although many patients continue to ex-
press a preference for PCI, particularly now that we have re-
ports of the feasibility and safety of same-day discharge.
This is particularly applicable with radial access (or post-pro-
cedural deployment of a femoral closure device), and, in a US
registry study, 1339 patients discharged on the same day as
their procedure had similar 30 days readmission rates to
105,679 patients who stayed overnight.14 This is important be-
cause it is now recognised that readmission within 30 days
after PCI is associated with a signiﬁcant increase in 1 year
mortality.15
3. Left main stem disease
The trespass of PCI onto territory that was formerly surgical is
best illustrated by its increasing application in unprotected left
main stem disease. Registry data from the USA for 131 004
patients with unprotected left main stem disease show the
proportion treated with PCI increasing from 3.8% to 4.9% be-
tween 2004 and 2008. PCI recipients were older with more
comorbidities, probably accounting for their higher hospital
mortality compared with the overall cohort (13% vs. 5%).16
Technical improvements since 2008 have seen further increases
in the rates of PCI in unprotected left main stem disease, and
we now have randomised trial data conﬁrming its safety and
efﬁcacy in selected patients. Thus in the Korean PRECOM-
BAT trial of drug-eluting stenting vs. CABG in 600 patients,
Almanac 2012: Interventional cardiology 338.7% of patients in the stent group and 6.7% in the CABG
group met the primary end point (a composite of death, MI,
stroke and ischaemia-driven revascularisation at 12 months),
a difference signiﬁcant for the non-inferiority of stenting.17
As in previous randomised comparisons, the difference was
driven largely by a higher rate of repeat revascularisation in
stent recipients (9.0% vs. 4.2% after 2 years, p= 0.02).
Selection for revascularisation in left main stem disease has
traditionally been based on angiographic assessment, but a re-
cent study suggests that measurement of minimum lumen area
by intravascular ultrasound (IVUS) might be a better means of
selection in patients with ‘intermediate’ angiographic stenoses
in the range of 25–60%.18 Correlation between minimum lu-
men area and angiographic stenosis was poor, but a 6 mm2
area measurement provided a safe threshold for determining
revascularisation, the event-free survival being no worse in
the patients with an area measurement > 6 mm2 who did
not undergo revascularisation compared with the patients with
an area measurement < 6 mm2 who did. These were non-
randomised data, but point to a useful role for IVUS in the
management of left main coronary artery disease.
4. DES and stent thrombosis
The introduction of bare metal stents (BMSs) towards the end
of the last decade dramatically improved the performance and
safety of PCI, but it required drug-eluting technology to make
a signiﬁcant impact on restenosis rates. Concerns about an in-
creased risk of stent thrombosis with DESs19 appear to have
been exaggerated, particularly with the current generation of
DESs, but the beneﬁcial effects on restenosis have been borne
out. Thus a recent meta-analysis comparing sirolimus-eluting
and bare metal stents in patients with diabetes reported dra-
matic reductions in the need for repeat revascularisation with
the DES (HR 0.27, 95% CI 0.18–0.41) without any increase
in the risk of stent thrombosis.20 However, it has been the ever-
olimus-eluting stent that has emerged as the interventionists’
favourite, a meta-analysis of 13 randomised trials including
17,101 patients reporting thrombosis rates of only 0.7% during
21.7 months’ follow-up, compared with 1.5% in patients trea-
ted with any other type of DES.21 A further meta-analysis
pooled data from 49 randomised trials including 50,844 pa-
tients and came to similar conclusions by showing that everol-
imus-eluting stents had the lowest risk of stent thrombosis at
30 days and 1 year compared with other stents approved for
use in the USA, including BMSs.22 The difference in favour
of everolimus-eluting stents remained signiﬁcant at 2 years
when the odds of stent thrombosis were 0.34 (95% CI 0.19–
0.62) compared with paclitaxel-eluting stents and 0.35 (95%
CI 0.17–0.69) compared with BMSs.
Data on DESs in saphenous vein grafts are somewhat less
clear, but the limited available randomised trials do suggest
superiority compared with BMSs.23 For primary PCI, con-
cerns that the thrombotic environment might predispose to
DES thrombosis have not been fully realised, a pooled analysis
of 15 STEMI trials comparing ﬁrst-generation DESs with
BMSs reporting a lower requirement for target vessel revascu-
larisation with DESs (RR 0.51, 95% CI 0.43–0.61), with no
difference in the rate of stent thrombosis compared with
BMSs.24 Indeed, the risk of stent thrombosis during the ﬁrst
year was reduced for DESs (RR 0.80, 95% CI 0.58–1.12) butincreased thereafter (RR 2.10, 95% CI 1.20–3.69), suggesting
that the early beneﬁt of ﬁrst-generation DESs in primary
PCI is offset by a later increase in the risk of stent thrombosis.
Newer-generation DESs may overcome this drawback, but,
until we have sufﬁcient data, operators should carefully weigh
the differential risk of restenosis and stent thrombosis between
the two stent types.
Interest in bioresorbable stents has been enhanced by re-
ports from a phase II evaluation of imaging data 12 months
after implantation in 56 patients.25 The restenosis rate was
only 3.5%, and >95% of the stent struts were endothelialised.
Moreover, variable coronary dilatation in response to acetyl-
choline was observed, indicating some return of normal vaso-
motor responses. The results of randomised trials now in the
planning stage are eagerly awaited.
5. Optimal arterial access
Radial access for coronary angiography has now achieved
widespread application.26,27 One reason is the accumulating
evidence that it reduces bleeding risk and, perhaps because
of this, may reduce mortality in primary PCI.28 Thus a com-
prehensive meta-analysis pooling of all the data from random-
ised primary PCI trials comparing femoral with radial access
showed a nearly 50% mortality reduction in the radial
group.29 Whether this beneﬁcial effect is generalisable to every-
day clinical practice is unclear, but observational data support
the trial results and indicate the beneﬁt of radial access for pri-
mary PCI.30,31 Another potentially important advantage of ra-
dial access is its association with a reduced risk of kidney
injury, as reported in a large Canadian study of 69 214 patients
undergoing cardiac catheterisation.32 The mechanism is un-
clear and the largest trial comparing radial and femoral access,
the RIVAL trial, did not show a clear advantage for either ac-
cess route, although radial access appeared preferable in the
subgroup undergoing primary PCI.33 On the basis of current
evidence, the choice between radial and femoral access should
be individualised taking into account operator experience,
bleeding risk and patient preference.
6. Antiplatelet therapies––what’s new?
In patients undergoing PCI, dual antiplatelet therapy with
aspirin and clopidogrel remains central to guideline recom-
mendations. For clopidogrel, a pooled analysis of available
data favoured a loading dose of 600 mg, which was associated
with a 34% reduction in the rate of major adverse cardiac
events (MACE) without any increase in the risk of major
bleeding compared with a 300 mg loading dose.34 Now we
have randomised trial evidence conﬁrming that, compared
with the 300 mg loading dose, the 600 mg dose in primary
PCI is associated with signiﬁcant reductions in infarct size,
measured by median CKMB mass over 72 h (2070 vs.
3029 ng/ml).35 Continuing therapy with aspirin and clopido-
grel is usually recommended after PCI in both stable and pa-
tients with acute coronary syndromes (ACS), but the
antiplatelet effect of clopidogrel is variable, and high on-treat-
ment platelet reactivity can be demonstrated in 14.7–26.9% of
patients, depending on the test used.36 Part of this variability in
antiplatelet responsiveness is explained by the fact that clopi-
dogrel is a prodrug, and the enzymes that form its active
34 P. Meier, A. Timmismetabolites exhibit functionally distinct polymorphisms. How-
ever, a study from the Netherlands of 1069 clopidogrel-pre-
treated patients undergoing elective PCI found that loss-of-
function CYP2C19 carrier status explained only part of the
variability in platelet reactivity (13.0–20.6%), depending on
the test used.37 One approach to modifying high on-treatment
platelet reactivity in carriers of loss-of-function CYP2C19 vari-
ants is to use antiplatelet drugs metabolised by different path-
ways, and this was conﬁrmed by investigators from Korea in a
substudy of the CILON-T randomised trial.38 In patients with
loss-of-function CYP2C19 variants who were randomised to
dual antiplatelet therapy plus cilostazol, a selective phosphodi-
esterase-3 inhibitor, on-treatment platelet reactivity was signif-
icantly reduced compared with patients who received only
aspirin and clopidogrel. This effect of cilostazol was not seen
in non-carriers of the loss-of-function polymorphism. An alter-
native approach for modifying high on-treatment platelet reac-
tivity after PCI is to increase the dose of clopidogrel. However,
this was found ineffective in the GRAVITAS trial, the 6 month
rate of the composite of cardiovascular death, MI and stent
thrombosis being identical for groups randomised to high-dose
(150 mg daily) or standard-dose (75 mg daily) clopidogrel.39
Current guideline recommendations are for clopidogrel to
be stopped 12 months after DES deployment when endotheli-
alisation is complete, reducing the risk of thrombosis. Worry-
ingly, a clustering of late clinical events has been associated
with this policy, perhaps because of an increase in arachidonic
acid-induced platelet activation as reported in a recent UK
study,40 lending support to the accumulating evidence that
clopidogrel exerts some of its antiplatelet effects via this path-
way, independent of aspirin. Indeed, it has been suggested that
the discontinuation of aspirin instead of clopidogrel might be
more rational 1 year after stenting.41 This question will soon
be tested in the large GLOBAL-LEADERS randomised trial.
The limitations of dual antiplatelet therapy with aspirin and
clopidogrel have been further illustrated by the on-TIME-2
trial, in which patients undergoing primary PCI were random-
ised to additional prehospital tiroﬁban or placebo.42 The addi-
tion of tiroﬁban produced more effective platelet inhibition
than aspirin and clopidogrel alone, and this was associated
with a reduction in MACE and early stent thrombosis. On-
TIME-2 lends further support to guideline recommendations
for early glycoprotein IIb/IIIa inhibition together with dual
antiplatelet therapy in patients undergoing primary PCI.
6.1. Newer P2Y12 receptor inhibitors
These include prasugrel and ticagrelor, which now have guide-
line indications in ACS43 based on the TRITON and PLATO
randomised trials, which were the subject of recent review.44
TRITON randomised patients undergoing PCI for ACS to
either clopidogrel or prasugrel therapy for 12 months after
the procedure.45 Prasugrel showed superiority over clopidogrel
for the composite primary end point, driven mainly by peripro-
cedural MI. It also showed signiﬁcant risk reduction for stent
thrombosis. However, these beneﬁts came with an increased
risk of major and minor bleeding. In the PLATO trial of
ticagrelor vs. clopidogrel in patients with ACS managed med-
ically or with PCI,46 ticagrelor was superior with regard to the
primary composite end point of MACE, but, while minor
bleeding was more common with ticagrelor, the major bleedingrisk was comparable to that with clopidogrel. These random-
ised trials have conﬁrmed that more intensive platelet inhibi-
tion with prasugrel or ticagrelor delivers better clinical
outcomes in ACS, although there is a bleeding penalty, partic-
ularly it seems for prasugrel. The clinical outcome advantage
for both drugs is small in absolute terms, raising important
questions about cost-effectiveness. A US evaluation for prasu-
grel concluded it was ‘an economically attractive treatment
strategy’,47 but a more recent National Institute for Health
and Clinical Excellence (NICE) technology assessment was
more guarded, recommending prasugrel as an option in pa-
tients with STEMI if immediate primary PCI is necessary
(based on its rapid onset of action compared with clopidogrel),
or if diabetes is present or if stent thrombosis has occurred
during clopidogrel treatment.43 However, concern was ex-
pressed about its likely cost-effectiveness in other situations.
A recent health economic analysis based on the PLATO study
concluded that treating patients with ACS with ticagrelor for
12 months is associated with a cost per QALY (quality-ad-
justed life year) below generally accepted thresholds for cost-
effectiveness.48
6.2. Bivalirudin and heparin
Bivalirudin is now available for treatment of ACS and has rap-
idly gained a central role in primary PCI.49 It is a direct throm-
bin inhibitor with additional activity against thrombin
mediated platelet activation that showed superiority over a
combined regimen of heparin plus a glycoprotein IIb/IIIa
inhibitor in HORIZONS-AMI, due largely to a lower rate of
major bleeding (4.9% vs. 8.3%). All-cause mortality was lower
at 30 days, and we now have 3 year follow-up data conﬁrming
persistent mortality beneﬁt (5.9% vs. 7.7%), ensuring a guide-
line recommendation for bivalirudin in primary PCI.50 The
clinical beneﬁts of bivalirudin have also been associated with
cost-effectiveness, patient lifetime costs in the UK being £267
lower than for glycoprotein IIb/IIIa inhibitors.51 A small in-
crease in the rates of stent thrombosis with bivalirudin was
not seen in patients pretreated with heparin, and the mortality
beneﬁts of combining bivalirudin with heparin pretreatment
have since been reported from the SCAAR registry,52 leading
the editorialist to recommend dual therapy in patients under-
going primary PCI.53
Unfractionated heparin retains a class 1 recommendation
for use during PCI, but a recent meta-analysis of pooled data
from 23 studies has shown that enoxaparin is associated with
signiﬁcant reductions in the composite of death and MI and
in major bleeding rates compared with unfractionated hepa-
rin.54 These beneﬁts were greatest for primary PCI, but were
also seen in PCI for non-ST elevation MI and stable angina.
The time may be right for a change of policy in favour of
low-molecular-weight heparin during PCI.
7. Intravascular imaging––clinical beneﬁt?
The clinical beneﬁt of using IVUS to guide PCI remains con-
troversial, although a pooled analysis of seven randomised
BMS trials has concluded that IVUS-guided PCI is associated
with a reduced risk of in-stent restenosis.55 IVUS is also ﬁnd-
ing a role in assessing left main stem lesions for revascularisa-
tion.18 As a research tool, however, and for the validation of
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particularly valuable.56 Thus, in a recent study comparing cor-
onary CT angiography and IVUS for plaque volume measure-
ments, there was only modest agreement between the two
methods (Bland–Altman limits of agreement 67 to
+65 mm3), reﬂecting the limitations of coronary CT for
assessing the extent of coronary disease.57 While the ability
to image across the coronary arterial wall is a particular
strength of IVUS, the technology is limited by image resolu-
tion, which is considerably inferior to optical coherence
tomography (OCT). In a substudy of ODESSA, for example,
suboptimal stent deployment was identiﬁed by OCT at the le-
vel of individual stent struts, a detail that could never be repro-
duced by IVUS.58 Increasingly, OCT is being used to assess
stent strut endothelialisation, a recent Japanese study of ever-
olimus-eluting stent implantation showing that, of 5931 struts
assessed, 98.4% were endothelialised 8 months after implanta-
tion, an observation reﬂected in the low thrombotic risk for
these second-generation DESs.59
Intravascular imaging has also been used to assess plaque
stability, the PROSPECT trial conﬁrming that IVUS can dif-
ferentiate stable from unstable plaque and predict adverse
events.60 A key feature of unstable plaque is thin-cap athero-
sclerosis, and recent data remind us that the inﬂammatory
environment is an important determinant of instability, an
OCT study showing a clear association between the cap thick-
ness of plaques and inﬂammatory plasma markers such as
high-sensitivity C-reactive protein.61
8. Technical aspects of stenting––what have we learnt?
8.1. Overlapping stents
Re-endothelialisation of overlapping stent segments is slower,
and most operators prefer single stent deployment for that rea-
son.58 However, in the real world, overlapping stent deploy-
ment is often unavoidable, and, for DESs, the conventional
wisdom has been that homogeneous stents should be used to
avoid the elution of different pharmacological compounds
within the overlapping segment. This has now been challenged
by a Korean study of 1080 patients who received overlapping
DESs.62 The study showed that cardiac death, MI or target
lesion revascularisation occurred with similar frequency
regardless of whether the DESs were homogeneous or
heterogeneous.
8.2. Bifurcation stenting
Several studies have shown that a single, main vessel stent
deployment provides outcomes that are comparable––and of-
ten superior––to two-stent deployment. Thus a combined anal-
ysis of the NORDIC Bifurcation Study and the British
Bifurcation Coronary Study showed that, in patients random-
ised to ‘simple’ main vessel stenting, the composite MACE end
point at 9 months occurred in 10.1% of patients compared
with 17.3% of patients who underwent complex two-vessel
stenting (p= 0.001).63 However, questions remain, particu-
larly concerning the value of ﬁnal kissing balloon inﬂations
across the bifurcation following main-vessel stenting. This
was addressed in a large observational study of 1055 patients
undergoing bifurcation stenting.64 A comparative propensityanalysis of patients who did and did not have ﬁnal kissing
balloon inﬂations showed a higher incidence of MACE and
target lesion revascularisation, mostly in the main vessel, for
patients who had ﬁnal kissing balloon inﬂations. The pendu-
lum therefore has now swung away from ﬁnal kissing balloon
inﬂation, which may cause more harm than good.
9. Myocardial infarction––high-sensitivity troponin assays
Central to the diagnosis of acute MI is the demonstration of a
raised and changing troponin concentration in the ﬁrst 24 h
after symptom onset. The availability of high-sensitivity tropo-
nin (hsTn) assays is likely to see diagnostic thresholds fall, with
important implications for clinical management and cardiac
outcomes. Thus, in a recent study in which hsTn-I was mea-
sured in 1038 patients with suspected ACS, values below the
previous limit of detection (0.20 ng/ml) showed graded associ-
ation with death or non-fatal MI.65 In a further 1054 patients,
the diagnostic threshold was lowered to 0.05 ng/ml, and
attending physicians were invited to modify their management
accordingly. Rates of death and recurrent MI fell from 39% to
12% among patients with troponin concentrations of 0.05–
0.19 ng/ml, levels that would have been undetectable with con-
ventional troponin assays. The investigators concluded that
lowering the diagnostic threshold using hsTn assays has the
potential to identify many high-risk individuals with suspected
ACS and produce major improvements in their prognosis.
It has always been the recommendation that the diagnostic
threshold level chosen for troponin should be based on a coef-
ﬁcient of variation of #10%, but new guidance is for the 99th
centile value to be adopted regardless of assay imprecision.66
The potential clinical impact of this change in guidance was
evaluated in the same cohort as reported previously,65 this time
using a diagnostic threshold of 0.012 lg/l (coefﬁcient of varia-
tion 20.8%)67 At 1 year, patients with troponin concentrations
of 0.012–0.049 lg/l, who previously would have escaped a
diagnosis of MI, were more likely to be dead or readmitted
with recurrent MI than those with troponin concentra-
tions < 0.012 lg/l (13% vs. 3%, p< 0.001). The authors con-
cluded that lowering the diagnostic threshold to the 99th
centile and accepting greater assay imprecision would not only
identify more patients at high-risk of recurrent MI and death,
but also increase the diagnosis of MI by 46%. It remains to be
established whether reclassiﬁcation of these patients and treat-
ing them according to conventional MI guidelines will improve
their outcomes.
hsTn assays will not only cause diagnostic thresholds for
acute MI to fall, but may also allow the identiﬁcation of pa-
tients with apparently stable coronary disease who have vul-
nerable coronary lesions.68 Thus a recent study has shown a
strong correlation between hsTn-T and non-calciﬁed plaque
burden (r= 0.79, p< 0.001) in 124 patients with stable angi-
na undergoing CT angiography, patients with remodelled non-
calciﬁed plaque having the highest hsTn-T values.69 hsTn as-
says have already found clinical application for the early diag-
nosis of MI in patients with chest pain attending the
emergency department. In the randomised assessment of treat-
ment using panel assay of cardiac markers (RATPAC) trial,
the use of hsTn-I within a panel of biomarkers allowed suc-
cessful discharge of 32% of patients compared with 13% of
patients receiving standard diagnostic procedures.70 Beyond
36 P. Meier, A. Timmistheir central role for diagnosis, troponins also provide a mea-
sure of the severity of MI, and, in a report from the GRACE
registry,71 incorporating 16 318 patients with non-ST elevation
MI, each 10-fold increase in the troponin ratio was associated
with stepwise increments in ventricular arrhythmias, heart fail-
ure, cardiogenic shock and death.72
10. Non-culprit lesions in ACS
The importance of myocardial salvage during the acute phase
of infarction is emphasised by the fact that prognosis is driven
largely by ultimate infarct size. We could therefore hypothesise
that treating all signiﬁcant lesions is beneﬁcial. One of the ﬁrst
primary PCI randomised trials testing this hypothesis was re-
ported last year. Among 214 patients with multivessel disease,
adverse event rates during a mean follow-up of 2.5 years were
higher with culprit-only PCI compared with multivessel PCI,
whether performed during the index procedure or as a staged
procedure afterwards.73 However, the trial was small and not
deﬁnitive, a more recent meta-analysis ﬁnding in favour of cul-
prit-only primary PCI with a staged strategy for non-culprit le-
sions.74 This has become the guideline recommendation and
was further supported by the analysis of observational data
from the HORIZONS-AMI trial in which outcomes for 275
patients treated with single-procedure stentings were compared
with outcomes for 393 patients treated with staged proce-
dures.75 The single-procedure group received signiﬁcantly
more stents yet had a signiﬁcantly higher 12 month mortality
(9.2% vs. 2.3%) than the staged procedure group. The weight
of evidence is now ﬁrmly in favour of culprit-only stenting dur-
ing primary PCI.
10.1. Infarct size and myocardial salvage
Circadian rhythms in the onset of MI are well established, the
morning hours being the period of greatest risk. Intriguingly,
infarct size appears to show similar circadian variation, a ret-
rospective analysis of 811 patients with STEMI showing that
creatine kinase (CK) and troponin I curves peak between
06:00 h and noon.76 Myocardial salvage in response to reperfu-
sion therapy with PCI is the major strategy for limiting infarct
size therapeutically and can now be quantiﬁed by cardiovascu-
lar magnetic resonance (CMR). A study of 208 patients pre-
senting with STEMI conﬁrmed that the extent of salvage
measured by CMR is closely related to long-term prognosis,
patients with a myocardial salvage index (MSI) above the med-
ian level having a lower number of adverse cardiovascular
events (7 vs. 26) and deaths (2 vs. 12) after 18.5 months than
patients with MSI below the median level.77 Myocardial reper-
fusion, however, can itself exacerbate injury, by a variety of
mechanisms which include interstitial haemorrhage. This can
be detected by CMR and was reported in 25% of patients with
STEMI treated successfully by primary PCI.78 The presence of
haemorrhage was an independent predictor of adverse remod-
elling, as reﬂected by increased left ventricular (LV) end-sys-
tolic volume at 3 months. The importance of interstitial
haemorrhage as a predictor of LV remodelling was emphasised
by the improvement in the area under the receiver operating
characteristic curves from 0.699 to 0.826 when it was added
to LV ejection fraction and infarct size in the predictive model.
Microvascular obstruction after primary PCI is also predictiveof remodelling, and in another CMR study was found to cor-
relate signiﬁcantly with reperfusion haemorrhage (r2 = 0.87,
p< 0.001).79
Strategies to protect against reperfusion injury remain high
on the research agenda and have been the subject of recent re-
view.80 In one study the effect of erythropoietin was tested
based on beneﬁcial experimental effects for reducing infarct
size.81 However, the study was negative, with patients random-
ised to erythropoietin (50,000 IU) before primary PCI showing
an increased incidence of microvascular obstruction and LV
dilatation without reduction in infarct size compared with pa-
tients randomised to placebo. Another study using forearm
plethysmography tested a bradykinin B2 receptor antagonist,
based on the hypothesis that endogenous bradykinin is a medi-
ator of reperfusion injury.82 The investigators found that re-
mote ischaemic preconditioning abolished the impairment of
endothelium-dependent vasomotor function induced by pleth-
ysmography, but bradykinin receptor blockade had no effect.
Nevertheless, the ﬁnding that conditioning stimuli provide a
clinically applicable means of protection against reperfusion in-
jury was not new and has been replicated in other more recent
clinical trials. A comparative primary PCI study of post-condi-
tioning by staccato versus abrupt reperfusion, for example,
showed that the staccato protocol was associated with better
preservation of microvascular function and LV dimensions
12 months later.83 Staccato reperfusion was also partially effec-
tive in another primary PCI study in which patients were ran-
domised to staccato reperfusion versus control. Infarct size
was unaffected, except in patients with large areas at risk in
whom it was signiﬁcantly reduced by post-conditioning.84
The beneﬁts of intra-aortic balloon counterpulsation
(IABC) when cardiogenic shock complicates acute MI are gen-
erally accepted. Recently, the role of IABC for reducing infarct
size in haemodynamically stable patients with anterior MI was
tested in a randomised trial of 337 patients.85 Infarct size at 3–
5 days determined by MRI showed no signiﬁcant difference
between the groups, but those patients randomised to IABC
showed a trend towards more vascular complications. The
authors concluded that IABC produces no clinical beneﬁt in
this group of patients.
11. Contrast-induced acute kidney injury (CI-AKI)
Whether newer contrast agents, such as iso-osmolar contrast,
have an impact on the CI-AKI risk is controversial.86 Risk
of CI- AKI is particularly high in patients presenting with an
ACS, and recent data conﬁrm it has a signiﬁcant impact on
clinical outcomes, including the length of hospital stay and
mortality.87,88 The ACS setting offers little time to apply
reno-protective measures, and strategies requiring up to 12 h
of prehydration are clearly impractical. The need for a change
in practice was emphasised by Wi et al.,87 who concluded that
renal function should be measured at the baseline and after
primary PCI, to reﬁne risk stratiﬁcation. Meanwhile consider-
ation should be given to reno-protection with bicarbonate,
which has been reported to be more effective than normal sal-
ine using short-infusion or single bolus protocols.89 In certain
subgroups, such as patients requiring urgent surgery for infec-
tive endocarditis, preoperative coronary angiography does not
appear to increase the risk of acute kidney injury,90 but, in
general, contrast exposure should be kept at as low a level as
Almanac 2012: Interventional cardiology 37possible during primary PCI. Meanwhile, randomised trials
testing short-duration prehydration protocols or bolus appli-
cations of potentially reno-protective substances are needed.
12. Carotid artery stenosis––is stenting still an option?
Life style adjustment and secondary prevention drugs may not
always be effective in protecting against the progression of car-
otid atherosclerosis. A recent trial of weight reduction with
rimonabant, for example, reported that a 5% reduction in
body weight over 30 months failed to inﬂuence the progression
of carotid disease compared with patients who received pla-
cebo.91 Many patients therefore require an interventional solu-
tion to their carotid disease, but whether this should be
surgical or percutaneous remains contentious.92 A large ran-
domised trial of 2502 patients with symptomatic or asymptom-
atic carotid stenosis showed no signiﬁcant difference in the
estimated rates of the primary composite end point (periproce-
dural stroke, MI, or death or any ipsilateral stroke within
4 years) and no differential treatment effect by symptomatic
status.93 However, a recent meta-analysis pooling data from
11 randomised trials comparing carotid endarterectomy
(CEA) with carotid artery stenting (CAS) showed that the peri-
procedural risk of mortality or stroke was lower for CEA (OR
0.67, 95% CI 0.47–0.95), mainly driven by a decreased risk of
minor stroke, whereas the risk of death or disabling stroke was
similar between the two groups. The odds of periprocedural
MI or cranial nerve injury were signiﬁcantly higher in the
CEA group.94 Current NICE guidelines recognise CAS as a
treatment option for patients with symptomatic carotid artery
stenosis, but emphasise that patients need to understand the
risk of stroke and other complications associated with this pro-
cedure. Patient selection should be carried out by a multidisci-
plinary team.95
For asymptomatic carotid artery disease, the situation is
even less clear. We know that patients with carotid stenosis
undergoing cardiac surgery for their coronary artery disease
have an increased periprocedural stroke risk and probably
should be considered for treatment even if asymptomatic.
The American guidelines recommend CEA if the stenosis is
P80%, either before or combined with CABG. CAS before
CABG is an alternative option with good results in patients
who are considered ‘high risk’ for CEA.96 Attempts to reﬁne
risk prediction in such patients have been the subject of consid-
erable research, a recent carotid ultrasound study reporting
that the total plaque area (HR 1.29, 95% CI 1.08–1.55), the
number of plaques (HR 1.14, 95% CI 1.02–1.27) and the num-
ber of segments with plaque (HR 1.45, 95% CI 1.09–1.93) were
all signiﬁcantly associated with the 5 year risk of cerebrovascu-
lar events.97
13. Transcatheter aortic valve implantation
Transcatheter aortic valve implantation (TAVI) in older high-
risk patients has yielded excellent results in most centres, the
2 year follow-up of patients in the PARTNER trial supporting
the procedure as an alternative to surgery in high-risk pa-
tients.98 Thus improvement in valve areas was similar for
TAVI and for surgery, with comparable rates of death and
stroke during follow-up. However, paravalvular regurgitation
was more common after TAVI and has been associated withsigniﬁcantly worse outcomes, the German registry reporting
higher in-hospital mortality, even after multivariate adjust-
ments for potential confounders (OR 2.50, 95% CI 1.37 to
4.55).99 Another cause for concern is the potential for myocar-
dial injury during TAVI, as evidenced by elevations of CK-MB
in 77% of 101 patients undergoing uncomplicated proce-
dures.100 Median maximal CK-MB levels were higher for
transapical than transfemoral access (22.6 ml vs. 9.9 ml), but
were unaffected by the presence of coronary artery disease.
Elevations of cardiac troponin T were also observed and were
predictive of cardiac death at 9 months. Clearly, therefore,
TAVI, like surgery, is commonly associated with some degree
of myocardial injury that is not benign. In most other respects,
however, TAVI appears safe and has been associated with
important symptomatic beneﬁts, as reﬂected in the improve-
ment in the health-related quality of life reported by the
PARTNER investigators.101 Smaller studies have reinforced
these ﬁndings by reporting improvement in the 6 min walking
distance and the quality of life scores, while brain natriuretic
peptide (BNP) levels decline substantially.102 Added to this is
the cost-effectiveness of TAVI in US and UK analyses, and
it seems certain that indications will continue to expand.103,104
Indeed, off-label TAVI is commonplace, with reported out-
comes that are comparable to on-label procedures.105 Para-
doxically, increasing TAVI activity appears to have led to a
signiﬁcant increase in referrals for surgical aortic valve replace-
ment,106 with Manchester, for example, seeing a 37% increase
in surgical AVR activity within 2 years of the start of a TAVI
programme.107
14. Percutaneous mitral valve repair
The development of percutaneous systems for mitral valve re-
pair in patients with severe mitral regurgitation has proved
more challenging than TAVI. NICE gave a guarded verdict
on the MitraClip device in 2010, recommending it to only be
used with ‘special arrangements for clinical governance, con-
sent and research of patients who are well enough for surgical
mitral valve leaﬂet repair’.108 This was based on the ﬁndings of
the endovascular valve edge-to-edge REpair study (EVER-
EST) investigators in an observational study of 107 patients
with moderate or severe mitral regurgitation, which reported
a successful MitraClip implant in 74% of patients, of whom
66% achieved freedom from death, mitral valve surgery and
severe mitral regurgitation (P3+).109 Since then the EVER-
EST investigators have undertaken a further observational
study in 78 older patients at a high risk of conventional sur-
gery, which showed that the MitraClip device reduced mitral
regurgitation in the majority of patients, with improvement
in symptoms associated with signiﬁcant LV reverse remodel-
ling over 12 months.110 The beneﬁts of the MitraClip appear
closely related to its efﬁcacy in reducing mitral regurgitation,
the midterm outcomes showing signiﬁcant association with
the acute haemodynamic response.111
14.1. Alcohol septal ablation in hypertrophic cardiomyopathy
Three studies have recently reported longer-term outcomes
after alcohol septal ablation in symptomatic patients with
hypertrophic cardiomyopathy (HCM). The results have been
encouraging. Among 874 patients with class III or IV symp-
38 P. Meier, A. Timmistoms in a US study, six (0.7%) died in relation to the proce-
dure, and survival estimates at 1, 5 and 9 years were 97%,
86% and 74%, respectively.112 Symptoms improved to class
I or II in all but 5% of cases, although 13% required repeat
ablation and 3% required surgical myomectomy. In a Cana-
dian study of 649 patients with HCM, 38% were managed
conservatively, and 62% underwent invasive therapy with
alcohol septal ablation (21%), surgical myomectomy (71%)
or dual chamber pacing (8%).113 In multivariate analysis, inva-
sive therapy was independently associated with better overall
survival (HR 0.6; 95% CI 0.4–0.97, p= 0.04), but not with
HCM-related survival. Among the invasive group, the pace-
maker-treated group fared less well than patients treated with
septal ablation or myomectomy, questioning the call for a
reappraisal of pacemaker therapy in a recent Spanish study
that reported favourable long-term results in a group of 50 pa-
tients.114 Finally, a Scandinavian study reported marked
reductions in outﬂow tract gradients in response to 313 abla-
tion procedures in 279 patients with HCM, of whom 94%
had class III/IV symptoms. Only 21% had class II/IV symp-
toms at 1 year, with little change thereafter. Estimated survival
rates at 1, 5 and 10 years were 97%, 87% and 67%, respec-
tively, and were comparable to survival rates in an age- and
gender- matched population. Taken together, these studies tes-
tify to the long-term beneﬁts of alcohol septal ablation in
HCM, which appears to be a valid alternative to surgery in
symptomatic HCM that does not respond to medical therapy.
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